Yating Wang

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant

Fanglei Zuo, Hassan Abolhassani, Likun Du et al. · Nature Communications · 2022 · 161 citations · Full text

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Ticiana Leal, Yating Wang, Afshin Dowlati et al. · Journal of Clinical Oncology · 2020 · 131 citations

Ecog-acrin Ea5161, Immunotherapy, Maintenance Nivolumab +17

How Does COVID-19 Affect China’s Insurance Market?

Yating Wang, Donghao Zhang, Xiaoquan Wang et al. · Emerging Markets Finance and Trade · 2020 · 131 citations

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

Yanhui Chen, Quanxing Liu, Zhiming Chen et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 104 citations · Full text

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

Zofia Piotrowska, Yating Wang, Lecia V. Sequist et al. · Journal of Clinical Oncology · 2020 · 103 citations

Sclerostin, Pathology, Phase Ii Study +21